New dupixent copycat drug tested in healthy volunteers
NCT ID NCT07502534
First seen Apr 04, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This early-stage trial compares a new drug called IBI3027 to the approved medication Dupixent. It involves 180 healthy Chinese men who receive a single injection of either drug. The goal is to see if IBI3027 is absorbed and cleared from the body similarly to Dupixent, and to check for any safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qingdao University Affiliated Hospital
Qingdao, Shandong, Shandong Province, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3027 (a monoclonal antibody injection)
What this could lead to
If successful, this could show that IBI3027 is a safe and equivalent alternative to Dupixent, potentially offering a more affordable treatment option for conditions like asthma or eczema.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only tests bioequivalence and safety, not effectiveness. The results may not predict how the drug works in people with the disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.